Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acheflan is a topical anti-inflammatory phytomedicine developed and marketed by Aché Laboratórios Farmacêuticos S.A. in Brazil. It is derived from the essential oil of *Cordia verbenacea* DC, a plant native to the Brazilian Atlantic Forest. The product is standardized to alpha-humulene, which serves as the primary active marker. Its mechanism of action involves the inhibition of pro-inflammatory mediators, specifically reducing the production of tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), as well as decreasing the expression of cyclooxygenase-2 (COX-2). Acheflan is indicated for the local treatment of inflammatory conditions such as tendinitis, muscle pain, lower back pain, and injuries resulting from trauma, such as sprains and contusions. It was the first pharmaceutical product entirely researched and developed in Brazil, resulting from a seven-year collaboration between Aché and national universities.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cordia verbenacea essential oil.